Cavidi AB develops and manufactures instruments and assays for HIV viral load diagnostics. Based on the proven chemistry of current manual test ExaVir Load, the company is now in the final phases of development of a new fully automated viral load diagnostic platform. This platform, Ziva™, aims to meet the need for cost-effective monitoring in high-disease burden countries. Commercialization is underway, and a distribution agreement is established with a top 10 global diagnostic company that will help Cavidi bring Ziva to market.

The WHO has defined an ambitious treatment target to help end the AIDS epidemic: 90% of all people living with HIV will be diagnosed, 90% of these will get access to antiretroviral therapy, and 90% of these will have viral suppression. This, combined with a WHO recommendation to use viral load technology to monitor HIV patients under treatment, is expected to drive a great demand for Cavidi’s innovative solutions.

Cavidi has approximately 45 employees, and is headquartered in Uppsala, Sweden.

Responsible partner:Veronica Byfield Sköld

Impilo board members:Fredrik Strömholm
Veronica Byfield Sköld


No. of employees:Approx. 45

CEO:John Reisky de Dubnic

Acquisition date:February 2018